Avacincaptad pegol in geographic atrophy secondary to age-related macular degeneration: a profile of its use

Funding The preparation of this review was not supported by any external funding.

Authorship and conflict of interest A. Zhuang-Yan and H. A. Blair are salaried employees of Adis International Ltd/Springer Nature and declare no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.

Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability Not applicable.

Additional information about this Adis Drug Review can be found here. 

Avacincaptad pegol (IZERVAY^TM), a complement C5 inhibitor, is a promising new treatment option for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). In phase 2/3 (GATHER1) and phase 3 (GATHER2) trials in adults with non-center point involving GA secondary to AMD, monthly intravitreal injection of avacincaptad pegol demonstrated a significant reduction in GA lesion growth rate over a period of 12 months. There were no significant differences in the mean change in best-corrected visual acuity (BCVA) and low-luminance BCVA between the avacincaptad pegol and sham groups. Avacincaptad pegol was generally well tolerated, with the most common adverse reactions being conjunctival hemorrhage, increased intraocular pressure, blurred vision, and choroidal neovascularization. Preliminary data from the 24-month analyses of GATHER2 have shown continued efficacy up to 24 months.

  
© Springer Nature Switzerland AG 2024